Economic evaluation of sorafenib in the treatment of hepatocellular carcinoma in Canada

References

• El-Serag HB, Rudolph L. Hepatocellular Carcinoma: Epidemiology and Molecular Carcinogenesis. Gastroenterology 2007;132:2557-76
   PubMed Web of Science ®Google Scholar
• Parkin DM, Bray F, Ferlay J, et al. Estimating the world cancer burden: Globocan 2000. Int J Cancer 2001;94:153-6
   PubMed Web of Science ®Google Scholar
• GLOBOCAN 2002, IARC http://www-dep.iarc.fr/(accessed on 22nd September, 2005)
   Google Scholar
• Dyer Z, Peltekian K, van Zanten SV. Review article: the changing epidemiology of hepatocellular carcinoma in Canada. Aliment Pharmacol Ther 2005;22:17-22
   PubMed Web of Science ®Google Scholar
• Castells A, Bruix J, Bru C, et al. Treatment of hepatocellular carcinoma with tamoxifen: a double-blind placebo-controlled trial in 120 patients. Gastroenterology 1995;109:917-22
   PubMed Web of Science ®Google Scholar
• Group C. Tamoxifen in treatment of hepatocellular carcinoma: a randomised controlled trial. CLIP Group (Cancer of the Liver Italian Programme). Lancet 1998;352:17-20
   Google Scholar
• Lai CL, Lau JY, Wu PC, et al. Recombinant interferon-alpha in inoperable hepatocellular carcinoma: a randomized controlled trial. Hepatology 1993;17:389-94
   PubMed Web of Science ®Google Scholar
• Llovet JM, Bruix J. Systematic review of randomized trials for unresectable hepatocellular carcinoma: Chemoembolization improves survival. Hepatology 2003;37:429-42
   PubMed Web of Science ®Google Scholar
• Llovet JM, Sala M, Castells L, et al. Randomized controlled trial of interferon treatment for advanced hepatocellular carcinoma. Hepatology 2000;31:54-8
   PubMed Web of Science ®Google Scholar
• Grimaldi C, Bleiberg H, Gay F, et al. Evaluation of antiandrogen therapy in unresectable hepatocellular carcinoma: results of a European Organization for Research and Treatment of Cancer multicentric double-blind trial. J Clin Oncol 1998;16:411-17
   PubMed Web of Science ®Google Scholar
• GRETCH. Randomized trial of leuprorelin and flutamide in male patients with hepatocellular carcinoma treated with tamozifen. Hepatology 2004;40:1361-9
   PubMed Web of Science ®Google Scholar
• Raoul JL, Guyader D, Bretagne JF, et al. Prospective randomized trial of chemoembolization versus intra-arterial injection of 131I-labeled-iodized oil in the treatment of hepatocellular carcinoma. Hepatology 1997;26:1156-61
   PubMed Web of Science ®Google Scholar
• Madden MV, Krige JE, Bailey S, et al. Randomised trial of targeted chemotherapy with lipiodol and 5-epidoxorubicin compared with symptomatic treatment for hepatoma. Gut 1993;34:1598-600
   PubMed Web of Science ®Google Scholar
• Chung YH, Song IH, Song BC, et al. Combined therapy consisting of intraarterial cisplatin infusion and systemic interferon-alpha for hepatocellular carcinoma patients with major portal vein thrombosis or distant metastasis. Cancer 2000;88:1986-91
   PubMed Web of Science ®Google Scholar
• Falkson G, Moertel CG, Lavin P, et al. Chemotherapy studies in primary liver cancer: a prospective randomized clinical trial. Cancer 1978;42:2149-56
   PubMed Web of Science ®Google Scholar
• Melia WM, Johnson PJ, Williams R. Induction of remission in hepatocellular carcinoma. A comparison of VP 16 with adriamycin. Cancer 1983;51:206-10
   Google Scholar
• Choi TK, Lee NW, Wong J. Chemotherapy for advanced hepatocellular carcinoma. Adriamycin versus quadruple chemotherapy. Cancer 1984;53:401-5
   Google Scholar
• Falkson G, MacIntyre JM, Moertel CG, et al. Primary liver cancer. An Eastern Cooperative Oncology Group Trial. Cancer 1984;54:970-7
   Google Scholar
• Falkson G, MacIntyre JM, Schutt AJ, et al. Neocarzinostatin versus m-AMSA or doxorubicin in hepatocellular carcinoma. J Clin Oncol 1984;2:581-4
   PubMed Web of Science ®Google Scholar
• Bezwoda WR, Weaving A, Kew M, et al. Combination chemotherapy of hepatocellular cancer. Comparison of adriamycin + VM 26 + 5-fluorouracil with mAMSA + VM 26 + 5-fluorouracil. Oncology 1987;44:207-9
   Google Scholar
• Lai CL, Wu PC, Chan GC, et al. Doxorubicin versus no antitumor therapy in inoperable hepatocellular carcinoma. A prospective randomized trial. Cancer 1988;62:479-83
   Google Scholar
• Falkson G, Cnaan A, Simson IW, et al. A randomized phase II study of acivicin and 4′deoxydoxorubicin in patients with hepatocellular carcinoma in an Eastern Cooperative Oncology Group study. Am J Clin Oncol 1990;13:510-15
   PubMed Web of Science ®Google Scholar
• Ishikawa T, Ichida T, Sugitani S, et al. Improved survival with oral administration of enteric-coated tegafur/uracil for advanced stage IV-A hepatocellular carcinoma. J Gastroenterol Hepatol 2001;16:452-9
   PubMed Web of Science ®Google Scholar
• Yeo W, Zee B, Leung W, et al.A phase III study of doxorubicin versus PIAF for inoperable HCC. ASCO Annual Meeting Proceedings. J Clin Oncol 2004;22:4026
   Google Scholar
• Llovet JN. Systematic review: evidence-based management of hepatocellular carcinoma – an updated analysis of randomized clinical trials. Alimen Pharmcol Ther 2006;23:1535-47
   PubMed Web of Science ®Google Scholar
• Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, de Oliveira AC, Santoro A, Raoul JL, Forner A, Schwartz M, Porta C, Zeuzem S, Bolondi L, Greten TF, Galle PR, Seitz JF, Borbath I, Häussinger D, Giannaris T, Shan M, Moscovici M, Voliotis D, Bruix J;SHARP Investigators Study Group. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008;359:378-90
   PubMed Web of Science ®Google Scholar
• Health Canada: Drug Product Database. Available at http://www.hc-sc.gc.ca/dhp-mps/prodpharma/databasdon/index-eng.php (accessed August 9, 2007)
   Google Scholar
• U.S. Food and Drug Administration: Center for Drug Evaluation and Research. Available at http://www.w3.org/1999/xlink" xlink:href="http://www.fda.gov/cder/index.html (accessed August 9, 2007)
   Google Scholar
• Bruix J, Sherman M, Llovet JM, et al. Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver. J Hepatol 2001;35:421-30
   Google Scholar
• Bruix J, Sherman M. Practice Guidelines Committee, American Association for the Study of Liver Diseases. Management of hepatocellular carcinoma. Hepatology 2005;42:1208-36
   PubMed Web of Science ®Google Scholar
• Villa E, Moles A, Ferretti I, et al. Natural history of inoperable hepatocellular carcinoma: estrogen receptors' status in the tumor is the strongest prognostic factor for survival. Hepatology 2000;32:233-8
   PubMed Web of Science ®Google Scholar
• Kemp W, Pianko S, Nguyen S, et al. Survival in hepatocellular carcinoma: Impact of screening and etiology of liver disease. J Gastroenterol Hepatol 2005;20:873-81
   PubMed Web of Science ®Google Scholar
• Perry JF, Charlton B, Koorey DJ, et al. Outcome of patients with hepatocellular carcinoma referred to a tertiary center with availability of multiple treatment options including cadaveric liver transplantation. Liver Int 2007;27:1240-8
   PubMed Web of Science ®Google Scholar
• Butler SP, Morris DL, King J, et al. Survival in patients with hepatocellular carcinoma treated with intra-arterial I-131 labelled lipiodol. GI Cancer 2001;3:359-69
   Google Scholar
• Llovet JM, Burroughs A, Bruix J. Hepatocellular carcinoma. Lancet 2003;362:1907-17
   PubMed Web of Science ®Google Scholar
• Llovet JM, Bustamante J, Castells A, et al. Natural history of untreated nonsurgical hepatocellular carcinoma: rationale for the design and evaluation of therapeutic trials. Hepatology 1999;29:62-7
   PubMed Web of Science ®Google Scholar
• Cancer Institute NSW, DOH qtr Sep-07; MERU Reference: 08-006 (unpublished)
   Google Scholar
• Grusenmeyer PA, Wong YN. Interpreting the economic literature in oncology. J Clin Oncol 2007;2:196-202
   Google Scholar
• Konski A, Speier W, Hanlon A, et al. Is proton beam therapy cost effective in the treatment of adenocarcinoma of the prostate? J Clin Oncol 2007;24:3603-8
   Google Scholar
• Liberato NL, Marchetti M, Barosi G. Cost effectiveness of adjuvant trastuzumab in human epidermal growth factor receptor 2-positive breast cancer. J Clin Oncol 2007;6:625-33
   Google Scholar
• Griffin S, Bojke L, Main C, et al. Incorporating direct and indirect evidence using bayesian methods: an applied case study in ovarian cancer. Value Health 2006;2:123-31
   Google Scholar
• Canadian Agency for Drugs and Technologies in Health. Guidelines for the economic evaluation of health technologies: Canada, 3rd edn. Ottawa: The Agency, 2006. http://www.cadth.ca/media/pdf/186_EconomicGuidelines_e.pdf
   Google Scholar
• Gold MR, Siegel JE, Russell LB, et al., eds. Cost-effectiveness in Health and Medicine. New York: Oxford University Press, 1996
   Google Scholar
• Cheng A, Kang Y, Chen Z, et al. Randomized phase III trial of sorafenib versus placebo in Asian patients with advanced hepatocellular carcinoma. J Clin Oncol 2008;26:4509
   PubMed Web of Science ®Google Scholar
• Singer JD, Willett JB. Applied Longitudinal Data Analysis: Modeling Change and Event Occurrence. New York: Oxford University Press, 2003
   Google Scholar
• Delta PA, Brogan Inc. https://baesecure.broganinc.com/BAEPRDAPP/dpa/GridView.aspx (last accessed September, 2007)
   Google Scholar
• Ontario Schedule of Benefits for Physician Services under the Health Insurance Act; http://www.health.gov.on.ca/english/providers/program/ohip/sob/physserv/physserv_mn.html (last accessed Sept, 2007)
   Google Scholar
• Hospital participating in the Ontario Case Costing Project. http://www.occp.com, Ontario Schedule of Benefits for Insured Services (last accessed September, 2007)
   Google Scholar
• British Columbia Medical Services Commission Payment Schedule; http://www.hlth.gov.bc.ca/msp/infoprac/physbilling/payschedule/index.html (last accessed September, 2007)
   Google Scholar
• Costing obtained from University Health Network, Toronto. 2006
   Google Scholar
• Ontario drug benefit formulary/comparative drug index [database online]. Toronto: Ministry of Health and Long Term Care; 2006. Available: http://www.health.gov.on.ca/english/providers/program/drugs/odbf_eformulary.html (last accessed September, 2007)
   Google Scholar
• Nadler E, Eckert B, Neumann PJ. Do oncologists believe new cancer drugs offer good value? Oncologist 2006;11:90-5
   PubMed Web of Science ®Google Scholar
• Rocchi A, Menon D, Verma S, et al. The Role of Economic Evidence in Canadian Oncology Reimbursement Decision-Making: To Lambda and Beyond. Value Health 2008;11:771–83
   PubMed Web of Science ®Google Scholar
• Canadian Agency for Drugs and Technologies in Health (CADTH) CEDAC final recommendation and reasons for recommendation – Sunitinib malate (Accessed 10th December, 2007b) http://www.cadth.ca/media/cdr/complete/cdr_complete_Sutent_e_April-26-2007%20.pdf
   Google Scholar
• Bukowsky R, Cella D, Gondek K, et al. Effects of sorafenib on symptoms and quality of life results from a large randomized placebo-controlled study in renal cancer. Am J Clin Oncol 2007;30:220-7
   PubMed Web of Science ®Google Scholar